RecruitingMetastatic Non-small Cell Lung Cancer With MTAP Deletion
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Eligible age
18+ yrs
Accepts
All genders
Locations
26 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease.
- ✓ Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss.
- ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- ✓ Participants must have at least 1 measurable lesion as per RECIST v1.1.
You may not qualify if…
- ✕ Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy.
- ✕ Participants must not have symptomatic brain metastases or spinal cord compression.
- ✕ Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC).
- ✕ Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated.
- ✕ Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing.
- ✕ Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07063745 · last updated 2026-11-13